What biomarker tests are recommended for HER2-Positive Breast Cancer

Biomarker Testing for HER2-Positive Breast Cancer

Great question! Understanding what tests your care team recommends is an important part of your treatment planning. Let me walk you through the biomarker testing landscape for HER2-positive breast cancer.

Core Biomarker Tests You Should Have

According to NCCN Guidelines, here are the essential tests for HER2-positive breast cancer:

1. HER2 Testing (Already Done)

Since you have HER2-positive breast cancer, you've already had this critical test. HER2 testing is performed using two main methods:

• Immunohistochemistry (IHC): This test measures HER2 receptors on cancer cells. A score of 3+ means HER2-positive.
• In Situ Hybridization (ISH): This test counts copies of the HER2 gene. It's typically done when IHC results are unclear (2+) or to confirm results.

Why this matters: HER2-positive cancers have too many HER2 genes or receptors, which causes cells to grow and divide rapidly. This is actually good news because it means your cancer can be targeted with specific HER2-directed therapies like trastuzumab (Herceptin) and pertuzumab (Perjeta).

2. Hormone Receptor Status (ER/PR Testing)

This test checks for estrogen receptors (ER) and progesterone receptors (PR) on your cancer cells.

• ER-positive/PR-positive (HR+): Your cancer responds to estrogen, which may open up hormone therapy options in addition to HER2-targeted therapy
• ER-negative/PR-negative (HR-): Your cancer doesn't respond to estrogen, so treatment focuses on HER2-targeted and chemotherapy approaches

Why this matters: Your hormone receptor status significantly influences which treatment combinations your oncologist will recommend.

3. Tumor Mutation Testing

According to NCCN Guidelines, your tumor may be tested for specific DNA mutations such as:

• PIK3CA mutations: Can be targeted with specific therapies
• Other mutations (AKT1, PTEN, ESR1, NTRK, RET): May suggest additional treatment options

These tests help identify whether your cancer has specific genetic changes that respond to targeted drugs beyond HER2-directed therapy.

4. PD-L1 Testing (If Applicable)

This test checks for a protein called programmed death ligand 1 on your cancer cells. If present, it may indicate that your immune system could benefit from checkpoint inhibitor therapy combined with chemotherapy.

5. Tumor Markers (Blood Tests)

Your doctor may periodically check blood proteins such as:

• CEA (carcinoembryonic antigen)
• CA 15-3
• CA 27.29

Important note: These markers alone don't diagnose or monitor cancer reliably, but rising levels may suggest cancer progression. They're used selectively based on your individual situation.

Testing Approach: Quality Matters

NCCN Guidelines emphasize that:

• HER2 testing should be performed on all new primary or newly metastatic breast cancers
• Your laboratory should participate in quality assurance programs
• If initial testing was suboptimal or results are unclear, retesting may be recommended

Questions to Ask Your Oncologist

Since biomarker testing guides your treatment plan, here are important questions:

1. "Which biomarker tests have been completed on my tumor, and which results do I have?"
2. "Are there any additional biomarker tests you recommend based on my specific situation?"
3. "How do my hormone receptor status and any mutations affect my treatment options?"
4. "Will you retest if my cancer progresses or if I develop new tumors?"
5. "Can I get a copy of all my pathology and biomarker test results?"

Why Comprehensive Testing Matters

According to NCCN Guidelines for Patients, biomarker testing helps your care team:

• Choose the most effective treatment for YOUR specific cancer
• Identify whether you're eligible for targeted therapies beyond standard HER2 treatment
• Predict how your cancer might respond to different drugs
• Plan for potential resistance or progression

Moving Forward

If you haven't received all these tests, or if you're unclear about your results, this is a perfect conversation to have with your oncology team. Bring a list of questions and ask for copies of your pathology report and biomarker results—you have the right to this information.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.